BioSpace News Archive

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that MediciNova will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference which will be held from September 9 - 15, 2021.

Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will participate in three investment conferences in September.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

AptarGroup, Inc. announced that following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, it has completed the acquisition of a majority stake in Voluntis from the company’s reference shareholders and certain members of the management.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in five investor conferences taking place virtually throughout the month of September.

CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Wednesday, September 8, 2021.

Champions Oncology, Inc., leaders in transformative technology solutionsutilized in oncology drug discovery and development will report its financial and operational results for the first quarter ended July 31, 2021, on Monday, September 13, 2021, after market close.

R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE® Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.